Page 7 - Evidence Development News Today

On January 11, the Centers for Medicare and Medicaid Services announced a proposal to cover Food and Drug Administration-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease, including aducanumab, under Coverage with Evidence Development (CED) in CMS-approved randomized controlled trials. Currently, aducanumab is the only monoclonal

New York (January 24, 2022)— On January 11th, the Centers for Medicare and Medicaid Services (CMS) announced that it proposes to cover Food and Drug

/PRNewswire/ -- With so much misinformation surrounding the draft National Coverage Determination (NCD) from the Centers for Medicare and Medicaid Services...

WASHINGTON, Jan. 19, 2022 /PRNewswire/ -- With so much misinformation surrounding the draft National Coverage Determination (NCD) from the Centers...

Medicare has unveiled a plan to cover a controversial, expensive new Alzheimer’s drug, but has not said how much patients might pay

On January 11, 2022, the Centers for Medicare and Medicaid Services (“CMS”) published an anticipated proposed National Coverage Determination (“NCD”) decision memorandum that begins the...

Reston, VA – Yesterday, the Centers for Medicare and Medicaid Services (CMS) announced that it proposes to cover FDA-approved monoclonal antibodies

Medicare took a highly unusual step to restrict access to the controversial, pricey Alzheimer’s drug Aduhelm.

On November 12, 2021, the Centers for Medicare and Medicaid Services (CMS) issued a final rule rescinding the Medicare Coverage of Innovative Technology and Definition of "Reasonable and Necessary"...

Using clear terminology helps all parties manage the conditions for new drugs coming to market